ereditary spastic paraplegia (HSP) comprises a group of inherited neurodegenerative disorders with the shared characteristic of slowly progressive spasticity and weakness of the lower limbs. Conventionally, they are divided into "pure" or "complicated" forms depending on whether the paraparesis exists in isolation or with other major clinical features such as dementia, mental retardation, epilepsy, extrapyramidal disturbance, ataxia, deafness, retinopathy, optic neuropathy, peripheral neuropathy and/or skin lesions. HSPs can be inherited in an autosomal dominant, autosomal recessive or X-linked manner. The primary neuropathological feature of pure HSP is axonal degeneration in the long and descending tracts of the spinal cord, particularly in the terminal region. 1 To date, 31 loci have been identified, 13 of which are associated with autosomal dominant forms of HSP: SPG3A (MIM 182600) on 14q11-q21, 2 13 and SPG33 (MIM 610244) on 10q24.2. 14 Here, we evaluated a Chinese family with pure autosomal dominant HSP and excluded linkage to known HSP loci. We performed a genome wide scan and identified a candidate locus on 11p14.1-11.2, which may represent a novel genetic entity.
METHODS

Subjects
A four generation family with autosomal dominant hereditary spastic paraplegia from the Shandong province and Inner Mongolia Autonomous Region of China was studied. Nineteen members of the family were clinically investigated ( Figure 1 ). Diagnostic criteria for HSP were those of Harding. 15 The study was approved by the Expert Committee (equal to the Institutional Review Board) of the Xiangya Hospital of Central South University (China) and informed consent was obtained from all family members.
Genotyping and linkage analysis
Genomic DNA of all 19 family members were isolated from peripheral blood samples using standard techniques. Linkage to all known loci (SPG3A, SPG4, SPG6, SPG8, SPG9, SPG10, SPG12, SPG13, SPG17, SPG19, SPG29, SPG31, SPG33) was excluded by two point logarithm of odds (LOD) score analysis. Disease causing mutations in the most common known gene for SPG4 were also excluded by polymerase chain reaction, single strand conformation polymorphism. 16 Subsequently, a genome wide scan was performed using 382 microsatellite markers from the ABI Prism Linkage Mapping Set Version 2 (PE Applied Biosystems, USA). Information on additional markers to confirm and refine the interval was accessed through the Genome Database. Multiplexed PCR products were separated by capillary electrophoresis using an ABI PRISM 3100 Automated Sequencer (PE Applied Biosystems). Microsatellite marker allele data were analyzed by GENESCAN version 3.0 and GENOTYPER version 2.1 (PE Applied Biosystems).
Two point and multipoint linkage analyses were performed using the MLINK and LINKMAP programs of the LINKAGE package (version 5.1). 17 HSP was assumed to be an autosomal dominant trait with 95% penetrance. The disease frequency was set at 0.0001 and equal male and female recombination rates were assumed. Marker allele frequencies were set at 1/n, where n is the number of alleles observed. For multipoint analysis, the genetic distances between loci were obtained from the Marshfield, sex averaged, linkage map (http://research.marshfieldclinic.org/g enetics/Map -Markers/maps/IndexMap Frames.html) and converted to recombination fractions using Kosambi map function. Haplotypes were assigned based on the minimization of number of recombinations.
RESULTS
Clinical information
The complete pedigree is shown in Figure 1 . HSP was diagnosed in six living subjects who developed insidiously progressive gait disturbances. The proband (II:4) underwent brain MRI and electromyography of the upper and lower limbs which were all normal. The mode of inheritance in this family was clearly autosomal dominant with affected individuals because there was a male to male transmission. The family showed early age at onset of spastic paraplegia with a mean±standard deviation of 16.6±3.0 years. All patients displayed typical signs of spastic paraplegia characterized primarily by proximal weakness of the lower extremities with brisk reflexes and spastic gait abnormalities. The upper extremities showed normal tone and only very mild weakness of the small hand muscles. Urinary urgency was a common symptom and reported by 4 attended individuals (II:4, III:4, III:5, III:9). No cognitive impairment, sensation disturbances, extrapyramidal disturbances, ataxia, muscle atrophy or skin lesions were observed.
Exclusion analysis
Prior to performing genome wide screening of the family, the linkages to known autosomal dominant loci of SPG3A, SPG4, SPG6, SPG8, SPG9, SPG10, SPG12, SPG13, SPG17, SPG19, SPG29, SPG31 and SPG33 were tested: negative LOD score for markers flanking and within these loci were observed ( Table 1 ). The data indicated that the disorder in this kindred was not linked to the known HSP loci.
Genome wide scan
A genomic screening was subsequently undertaken using markers spaced, on average, at 10 cM intervals. Linkage was established to chromosome 11p12 when a significant LOD score was obtained with the consecutive (Table 2) . No other markers analyzed from the genome screening gave a LOD score>1.0. Twelve additional markers around D11S935 were tested in the family. The results of the two point analysis between the disease phenotype and the additional marker loci are shown in Table 2 . Multipoint linkage analysis with markers D11S1776, D11S1751, D11S1392, D11S4203, D11S935, D11S4083 and D11S4148 resulted in a maximum LOD score of 2.36 ( Figure 2 ).
The most probable disease haplotype was constructed according to the order of the Marshfield genetic map (Figure 1) . A particular haplotype associated with the disease was found in all affected members of the family. Two key recombinations were identified. The recombined haplotype of patients III:4, III:5, III:9 and III:11 suggests a recombination between markers D11S4180 and D11S1993 in meiosis of II:4, their mother. The second key recombination between markers D11S1324 and D11S2001 is deduced from patients IV:2 and III:5.
Combining the information of these two recombinations places the novel HSP entity at chromosome 11p14.1-11.2 over an 18.88 cM region between markers D11S1324 and D11S1993 (Figure 3 ). In the Human Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway), more than 40 genes have been mapped between markers D11S1324 and D11S1993.
DISCUSSION
The family studied here exhibited autosomal dominant hereditary spastic paraplegia. All patients showed typical signs of spastic paraplegia primarily characterized by proximal weakness of the lower extremities with brisk reflexes and spastic gait abnormalities. Urinary urgency was a common symptom in this family.
In this study, we described a Chinese family with HSP possibly linked to chromosome 11p14.1-p11.2, over an 18.88 cM interval between markers D11S1324 and D11S1933 with the maximal, two point LOD score of 2.36. It is likely that we did not obtain a LOD score>3 because there were not enough patients in this family. The SPG17 subtype was mapped to 11q12-14, 10 that does not overlap with the HSP locus we reported in this study. Additionally, the clinical features of this family were distinct from those of SPG17, whose clinical feature is spastic paraplegia with amyotrophy of the hands. We searched the Genome database for genes mapped between markers D11S1324 and D11S1993 and more than 40 genes had been mapped in this interval. HIPK3 (homeodomain interacting protein kinase 3), a Ser/Thr protein kinase, appears to be a good candidate gene that negatively regulates apoptosis by promoting FADD phosphorylation and enhances androgen receptor, mediated transcription. 18 Further studies are needed to demonstrate the specific gene alteration in this new genetic form of autosomal dominant HSP, which will likely bring new insights to the understanding of the pathogenesis underlying these degenerative diseases.
